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Abstract
Purpose. The feasibility of hyperthermic isolated limb perfusion (HILP) with tumor necrosis factor-a (TNFa ) and
cisplatin for the management of osteosarcoma was studied in the canine model.
Methods. During seven perfusions in six healthy mongrel dogs (weight 32±2 kg) technical aspects of HILP under mild
hyperthermia (39± 40Ê C) were studied. In ® ve experiments HILP was performed with TNFa alone (0.5 mg/l extremity
volume), and in two experiments TNFa was combined with cisplatin (25 mg/l extremity volume). During the perfusions
physiological parameters were monitored and TNFa and total cisplatin concentrations were determined.
Results. Perfusion conditions (pH, PCO 2, PO2, ¯ ow and pressure) remained within physiological ranges.Three dogs died
within 24 h despite a sublethal systemic concentration of TNFa that leaked from the perfusion circuit. Three dogs were
terminated; one dog after the second experiment in accordance with Dutch ethical rules; one dog showed an invagination of
the small bowel resulting in an ileus; one dog because of necrosis of the perfused limb.
Conclusions. This feasibility study in healthy dogs demonstrated that HILP withTNFa and cisplatin was associated with a
high mortality rate and does not allow us to treat dogs with spontaneous osteosarcoma with TNFa and cisplatin HILP.
Therefore, an alternative model should be used in the search for the ideal combination of perfusion agents for limb sparing
treatment in human osteosarcoma.
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Introduction
Osteosarcoma is the most frequent primary malignant
bone tumor in humans. Until the 1970s the most
common approach to the management of localized
osteosarcoma was surgical resection, amputation or
radiation therapy.
1 During the last decades a de® nite
role for neoadjuvant high-dose methotrexate and
cisplatin-based polychemotherapy was established.
1± 4
The potential local tumor effect of systemically
administered cisplatin, however, is limited due to the
nephrotoxicity and ototoxicity of cisplatin.Therefore
an attempt was made to increase the local effect of
cisplatin without increasing systemic toxicity by using
hyperthermic isolated regional limb perfusion (HILP)
with cisplatin in dogs with spontaneous osteosar-
coma.
5 These studies showed an acceptable locore-
gional toxicity, improved functional outcome at 6
and 12 weeks, and a steadily improving radiological
picture. However, the histological results were modest,
with none of the dogs showing a complete response
at 6 weeks after perfusion.The same experience was
found in patients with sarcomas of soft tissue and
bone treated with cisplatin HILP.
6 Results of recent
publications and of our own experience with a new
perfusion modality, which combines tumor necrosis
factor-a (TNFa ) and melphalan in patients with
recurrent melanoma or soft tissue sarcoma, are very
promising.
7,8 However, in six of eight evaluable
patients with unresectable osteosarcoma of the lower
limb treated with TNFa and melphalan HILP,
histological evaluation revealed moderate results with
‡ 80% necrosis in three patients, 50± 60% necrosis in
two patients and < 50% necrosis in one patient. After
TNFa and melphalan HILP, limb sparing surgery
was possible in six patients.
9As cisplatin is one of the
most active chemotherapeutics in the treatment of
osteosarcoma, it seems worthwhile to investigate the
results of HILP with TNFa and cisplatin. With the
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rcoma is a useful model for evaluation of new treat-
ment regimens in humans as rapid case accrual and
rapid time to reach measurable end points are
possible.
10The canine osteosarcoma therefore appears
to be a valid model for studying the potential treat-
ment of HILP with TNFa and cisplatin in the local
treatment of osteosarcoma of the extremity in
humans.To establish optimal HILP conditions using
TNFa and cisplatin for local tumor control in dogs




During seven experiments in six healthy mongrel dogs
with a mean average weight of 32 ± 2 kg and a mean
age of 6 ± 1 years, different aspects of HILP with
TNFa and cisplatin were studied. Preoperatively, all
dogs were thoroughly clinically evaluated at the
Central Animal Facility of the University of Gron-
ingen.The study was approved by the Animal Welfare
Committee of the Faculty of Medicine of the Gron-
ingen University.
Anaesthetics
The dogs fastened for 12 h and were anaesthetized
with thiopental (30 mg/kg body wt., i.v.) (Pentothal,
Abbott, Amstelveen, The Netherlands) and, after
muscle relaxation with pancuroniumbromide
(0.08 mg/kg body wt., i.v.) (Pavulon, Organon, Oss,
The Netherlands), the dogs were ventilated (Ohmeda
Modulus 2) with a mixture of O2 and iso¯ urane.The
oxygen concentration in the gas mixture was continu-
ously measured by means of an oxygen analyzer
(Ohmeda Modulus 2) and minute volumes (4± 6 l/
min) were adjusted to maintain an end-expiratory
CO2 concentration of 4± 5% (Siemens CO2 analyzer
930).The dogs were placed in the supine position on
a heated mattress to maintain their normal body
temperature of 38Ê C.
11 During the operations all
dogs were given about 2 l of glucose 5% via a cephalic
or internal jugular vein. Central arterial pressure was
recorded as well as an ECG and diuresis.
Operation and perfusion techniques
During anaesthesia the volume of the extremity was
measured using Archimedes’ rule (1.7± 2 l).The iliac
vessels were exposed under sterile conditions and
collateral vessels were clipped. Cannulas were inserted
into the artery (Bardic, 14± 18 F) and vein (Bardic,
14± 18 F). Both cannulas were connected to an
extracorporeal circuit consisting of an occlusive roller
pump, a cardiotomy reservoir and a bubble oxygenator
with heat-exchanger. A tourniquet made of nylon
was placed around the base of the extremity, using a
pin in the bone and a bandage around the middle to
complete the isolation of the limb from the systemic
circulation. The perfusate consisted of 350 ml 5%
dextran 40 in glucose 5% (Isodex, Pharmacia AB,
Uppsala, Sweden), 250 ml red blood cells (canine
blood donors), 250 ml plasma, 30 ml sodium
bicarbonate 8.4% and 0.5 ml 5000 IU/ml heparin
(Thromboliquine, Organon B.V., Oss, The
Netherlands).The mixture of oxygen, air and carbon
dioxide through the oxygenator was adjusted to
maintain the blood gas values within the physi-
ological range and, when necessary, bicarbonate was
added to adjust the pH value.
All perfusions were performed under mild hyper-
thermic conditions (39± 40Ê C) and optimal physi-
ological conditions.
12,13 Thermistor probes
(Electrolaboriet, Copenhagen, Denmark) were
inserted into the subcutaneous tissues and into a
muscle of the thigh just above the knee for continuous
monitoring of the temperatures during perfusion. In
the ® rst ® ve experimentsTNFa was the sole perfusion
agent, in the last two experiments TNFa was
combined with cisplatin. The dosage of TNFa
(0.5 mg/l extremity volume) (Boehringer, Ingelheim,
Germany) was calculated in order not to exceed ten
times the acceptable systemic levels (systemic,
10 m g/kg body wt).
14The dosage of cisplatin (20 mg/l
extremity volume) (Platinol 0.5 mg/ml, Bristol Myers
Squibb, Weesp, The Netherlands) used in the
perfusion had been established in a previous study
and was based on a maximum tolerable dose of
30 mg/l extremity volume.
15 Cisplatin was added to
the circulated perfusate in 10 min. During perfusion,
serum TNFa and total cisplatin levels were
determined in the regional and systemic circulation
at 0, 5, 15, 30, 45, 60, 75 and 90 min by ELISA and
¯ ameless atomic absorption spectophotometry
(FAAS), respectively. The perfusion time was 1 h,
followed by wash-out of the extremity with 3 l of
Isodex. Tourniquet, cannulas and clips were then
removed and the incisions in the vessels repaired.
Protamine hydrochloride (Hoffman La Roche,
Mijdrecht, The Netherlands) was administered, to
neutralize heparin, in a ratio of 1:1 to the initial dose
of heparin. All dogs were closely observed for at least
24 h. No anti-in¯ ammatory or analgesic drugs were
administered during follow-up.
All dogs were followed for local and systemic side
effects of TNFa and cisplatin perfusion, as well as
survival.
Results
Table 1 shows the characteristics of the seven experi-
ments in six dogs. During the experiments conditions
for perfusions (pH, PCO2, PO2) were kept within the
physiological ranges, as in human perfusions. Figure
1 shows the ¯ ow, blood pressure, perfusion pres-
sures, weight gain or loss of the extracorporeal circuit
and temperature during 60 min of perfusion in the
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TNFa was administered to the perfusion circuit. In
the last two experiments cisplatin was added. Figure
2 illustrates theTNFa concentrations (mean ± SEM)
in the perfused limb as well as in the systemic circula-
tion of the dog during perfusion and afterwards. Peak
TNFa concentrations in the perfused limb were
650 ± 158 ng/ml, and in the systemic circulation of
the dog they were 37 ± 15 ng/ml.The peak systemic
concentrations in the dog were in the same range as
those of TNFa and melphalan HILP used in the
treatment of humans at our institute.
16Figure 3 shows
the measured total cisplatin values in the last two
experiments. During the experiments we were not
able to perform any leakage monitoring by means of
radionuclear detection techniques which are used in
the clinical perfusion setting. Therefore leakage was
calculated afterwards according to Stehlin with the
amount of blood in the dogs estimated at 69 ml/kg
body weight.
17 Calculated leakage values are
summarized in Table 1.
Three dogs died within 24 h: the ® rst two during
the TNFa experiment; the third after TNFa and
cisplatin perfusion. Postmortem examination of these
animals did not provide any macroscopic or
microscopic evidence to explain the cause of death.
Three dogs were terminated; two due to treatment
complications. One dog showed an invagination of
the small bowel, resulting in an ileus and another was
terminated 1 week afterTNFa and cisplatin perfusion
because of necrosis of the perfused limb. The third
dog was terminated after the second experiment in
accordance with Dutch ethical rules.
Discussion
In the treatment of osteogenic sarcoma a distinction
can be made between systemic therapy and locore-
gional treatment. High-dose methotrexate-based
systemic chemotherapy is primarily administered in
order to eradicate possible micrometastatic disease,
and its use was a major breakthrough in the clinical
treatment of osteosarcomas in the 1970s.
1,2 Today,
about 60% of patients with resectable primary tumors
and no metastases at the time of the initial diagnosis
will be cured.
1
The primary objective in locoregional treatment is
to prevent local recurrence and allow limb salvage
procedures in an attempt to preserve limb function.
New surgical techniques and the development of
endoprosthetic materials, coupled with systemic
neoadjuvant chemotherapy, have offered less radical
surgery for 40± 80% of patients with osteosarcoma
since the 1980s.
1,18 Procedures that increase tumor
necrosis of the primary tumor, with reduction of
viable tumor cells and tumor volume, could contribute
to limb preservation strategies. Since its ® rst use,
cisplatin has been one of the most effective chemo-
therapeutic agents and has been incorporated in most
systemic treatment regimens for osteosarcoma. A
recent attempt to overcome its nephrotoxic and
ototoxic limitations by administering cisplatin in HILP
in the treatment of spontaneous canine osteosar-
coma was histologically modest.
5 Promising results
of recent publications and our own experience with a
new combination perfusion modality (TNFa and
melphalan) for recurrent melanoma or soft tissue
sarcoma, but moderate histological results in patients
with osteosarcoma, prompted us to investigate the
combination of TNFa and cisplatin in HILP for
osteosarcoma.
7± 9Since endothelial cells are supposed
to play a key role in the working mechanism of TNF,
osteosarcomas with a high extent of tumor vessels are
of particular interest.
Before application of TNFa and cisplatin HILP in
humans and client-owned osteosarcoma-bearing dogs,
the present feasibility study was performed in normal
healthy dogs. Despite sufficient experience in HILP
in dogs as well as in humans, an unexpected high
mortality rate was encountered. Although there was
no mortality related to the operation, three dogs died
within 24 h after perfusion (50%). This direct
postoperative mortality could not be explained by a
surplus of systemical leakage of TNF. In the experi-
ment, the dog with the highest leakage and, as a















1 35 2.7 1.3 0 8.7 II Dead < 24 h
2 31.5 1.4 0.6 0 0.3 II Dead < 24 h
3 26.5 2.3 1.15 0 5.1 II Ileus, terminated < 1 week
4 33.5 2.3 1.15 0 4.9 I Alive, experiment 1
5 31 1.9 1 0 6.1 n.a. Terminated, experiment 2
6 29.5 2.0 1 50 33.0 V Necrotic limb, terminated < 1 week
7 28.5 1.8 0.8 50 10.8 II Dead < 24 h
n.a., not applicable; dog 4 underwent two experiments; limb toxicity according to Wieberdink et al.
26; Grade I, no reac-
tion, objectively and subjectively; Grade II, slight erythema, oedema or loss of sensation; Grade III, considerable erythema
or oedema with some blistering, slight functional disturbances; Grade IV, extreme epidermiolysis and/or obvious damage to
the deep tissues causing de® nite functional disturbances; Grade V, reaction that might necessitate amputation.
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tions, survived immediately postoperatively, and the
dog with the lowest leakage (lowest systemic TNFa
concentrations) died within 24 h after perfusion. No
correlation between leakage and mortality rate could
be established. Maximal leakage encountered in these
experiments was 33%, this corresponds to 330 m g
TNFa given systemically per dog; since the average
dog weighs 33 kg, the dose of TNFa that reaches the
systemic circulation of the dog is sublethal (10 m g/
kg).
14Although only sublethal doses of TNFa leaked
to the systemical circulation, the clinical picture
resembled responses observed with lethal doses
(>100 m g/kg), characterized by progressive
Fig. 1. Perfusion characteristics (¯ ow, systemic blood pressure of the dog (BP); arterial catheter pressure (P-art); venous catheter pres-
sure (P-ven);extra-corporeal circulation (ECC);weight gain (+) or loss (± ) and temperature of the perfused limb (Ê C)) in time during
60 min of perfusion in seven experiments.
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19 Due to
the lack of facilities, we were not able to support the
dogs with intensive postoperative care, as is the case
after human TNFa HILP. In part this could explain
the observed direct postoperative mortality and
supports the need for intensive treatment after TNFa
HILP in the dog.
Three dogs survived the ® rst days after perfusion;
however, one dog developed an ileus and was
terminated within 1 week after perfusion. One dog
that underwent two experiments survived the ® rst
without morbid effects, but was terminated after the
second experiment according to Dutch ethical rules.
Leg toxicity consisted in slight erythema and edema
in all dogs except one in the cisplatin-treated group.
In this dog, necrosis of the perfused limb was
encountered, necessitating termination.We have never
observed necrosis of the perfused limb with the
cisplatin dose used (25 mg/l extremity volume) in
experiments where cisplatin was the sole perfusion
agent.
15 This observation may indicate that TNFa
might enhance the effect of cisplatin to the local
tissues of the perfused limb. The in vitro anticancer
potential, and overcoming cisplatin resistance with
the combination of TNFa and cisplatin in different
cell lines, has been established by others.
20± 22 Buell et
al. demonstrated an increased cellular cisplatin
accumulation and DNA adduct formation as the
possible cellular basis for the augmented cisplatin
cytotoxicity in the presence of TNF and hyperther-
mia.
23Recently,Anda et al. demonstrated that TNFa
selectively promoted the in vitro permeability of the
blood± brain barrier to CDDP without disrupting the
tight junctions.
24An improved penetration of cisplatin
into the interstitial space due to a higher permeability
of the vascular wall, combined with an increased
cellular cisplatin accumulation and DNA adduct
formation, could explain the observed necrosis of the
limb in this in vivo model with the cisplatin dose
used, which was previously non-toxic.
The observed mortality and morbidity that we
encountered in this canine study was similar to the
experience of Withrow and colleagues (unpublished
observations). The present results in normal elderly
mongrel dogs indicate that treatment of dogs with
spontaneous osteosarcoma using TNFa and cisplatin
HILP is not appropriate. Future research could focus
on postoperative monitoring and care in dogs after
TNFa HILP; perhaps a better alternative for testing
the effect of TNFa with cisplatin HILP is the use of
the rat osteosarcoma model described by Manusama
et al.,
25 since rats are much less susceptible to TNFa
than dogs.
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